secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001193125-25-157382
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista FY2025: FDA approved EKTERLY; cash $220.6M; R&D down, G&A up
---------------------------------------------------------------------

- FDA approved EKTERLY (sebetralstat) on July 7, 2025 as first oral on-demand HAE treatment; U.S. launch underway.
- Cash and marketable securities $220.6M at April 30, 2025, providing runway into 2027.
- R&D expenses $71.7M (down from $86.2M); G&A expenses $116.3M (up from $54.3M) driven by pre-commercial costs.
- Entered licensing agreements for sebetralstat in Japan (Kaken, $11M upfront) and Canada (Pendopharm).
- Six global regulatory submissions under review; new clinical data presented at EAACI, C1-INH, and EAC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525157382/0001193125-25-157382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525157382/d83017d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-157382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer